RegeneCure licenses bone regeneration tech from Yissum and Hadasit
This article was originally published in Clinica
Executive Summary
Regenerative medicine specialist RegeneCure has licensed a bone membrane implant technology from Yissum Research Development and Hadasit. The technology is at a very early stage, but may eventually be used to treat spine and craniofacial conditions.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.